Quantum Genomics, a biopharmaceutical research company developing new treatments in the field of cardiovascular diseases, announced that it will present the first results of clinical phase I studies conducted with QGC001 its first product, the 20 December 2013 on the occasion of the 33th days of Hypertension.
